About mannkind corp - MNKD
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.
MNKD At a Glance
MannKind Corp.
1 Casper Street
Danbury, Connecticut 06810
| Phone | 1-818-661-5000 | Revenue | 348.97M | |
| Industry | Pharmaceuticals: Major | Net Income | 5.86M | |
| Sector | Health Technology | 2025 Sales Growth | 22.228% | |
| Fiscal Year-end | 12 / 2026 | Employees | 592 | |
| View SEC Filings |
MNKD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 303.209 |
| Price to Sales Ratio | 5.104 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 97.56 |
| Enterprise Value to EBITDA | 30.399 |
| Enterprise Value to Sales | 5.969 |
| Total Debt to Enterprise Value | 0.227 |
MNKD Efficiency
| Revenue/Employee | 589,469.595 |
| Income Per Employee | 9,903.716 |
| Receivables Turnover | 8.933 |
| Total Asset Turnover | 0.588 |
MNKD Liquidity
| Current Ratio | 1.705 |
| Quick Ratio | 1.498 |
| Cash Ratio | 1.002 |
MNKD Profitability
| Gross Margin | 73.656 |
| Operating Margin | 16.116 |
| Pretax Margin | 0.403 |
| Net Margin | 1.68 |
| Return on Assets | 0.989 |
| Return on Equity | N/A |
| Return on Total Capital | 1.388 |
| Return on Invested Capital | 2.675 |
MNKD Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 112.08 |
| Total Debt to Total Assets | 59.757 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 100.422 |